IL17A and psoriasis: Last, we outline how preventing PD-L1:CD80 interactions or mutating the PD-L1 cytoplasmic domain in a model of psoriasis limits DC migration, interleukin-17 (IL-17) production by CD4+ T cells, and epidermal thickening associated with disease.